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The present study examines the ability of melatonin to protect striatal dopaminergic loss induced by 6-OHDA in a rat model
of Parkinson’s disease, comparing the results with L-DOPA-treated rats. The drugs were administered orally daily for a month,
their therapeutic or dyskinetic eﬀects were assessed by means of abnormal involuntary movements (AIMs) and stepping ability. At
the cellular level, the response was evaluated using tyrosine hydroxylase immunoreactivity and striatal ultrastructural changes to
comparebetweenL-DOPA-inducedAIMsandMelatonin-treatedrats.Ourﬁndingsdemonstratedthatchronicoraladministration
of Melatonin improved the alterations caused by the neurotoxin 6-OHDA. Melatonin-treated animals perform better in the motor
tasks and had no dyskinetic alterations compared to L-DOPA-treated group. At the cellular level, we found that Melatonin-treated
rats showed more TH-positive neurons and their striatal ultrastructure was well preserved. Thus, Melatonin is a useful treatment
to delay the cellular and behavioral alterations observed in Parkinson’s disease.
1.Introduction
Parkinson disease (PD) is an age-related disorder character-
ized by a progressive degeneration of dopaminergic (DAer-
gic) neurons of the substantia nigra pars compacta (SNc).
The etiology of DAergic neurons death is not known. How-
ever, reported data suggest oxidative stress as the probable
candidate to mediate in the original unknown cause. Studies
on patients’ brains have given evidences in support of this
hypothesis. Levels of reduced glutathione (GSH) are low
[1], while the level of the antioxidant enzyme manganese
superoxide dismutase (SOD) is high and is not paralleled
by a rise in glutathione peroxidase (GPX) [2]. Iron level
increase has also been reported [3] .S i n c ei r o ni sa b l et o
catalyze the Fenton reaction, this implies hydroxyl radical
(•OH) formation. Radical damage has been demonstrated
in lipids [4], proteins, and nucleic acids [5] of the SNc of
Parkinsonian patients. Thus, generation of reactive oxygen
species (ROS) caused by oxidative stress, together with a
relative lack of antioxidant defenses in the basal ganglia and
nigrostriatal DAergic pathway, is commonly considered the
ﬁnal cause of neuronal death [6, 7].
L-DOPA(LD)isthedrugofelectioninPDtherapy.LDis
converted by neuronal aromatic L-amino acid decarboxylase
into dopamine (DA), reestablishing DA levels in surviving
neurons, which, despite the treatment, continue to die [8, 9],
and whereas LD treatment is very successful in the early
stages of PD, it does not prevent disease progression, and in
the long term there are undesirable side eﬀects, such as the
development of dyskinesias [10–12]. Dyskinesia interferes2 ISRN Neurology
with physiological motor activity and constitutes a serious
challenge to the management of PD (for review see Obeso
et al. [13]). Previous studies have investigated the reasons
for such long-term problems. Some suggested mechanism
describes LD to elicit oxidative damage perpetuating the
cell death [14–17], and, after MPTP infusion, it seems that
LD generates 6-hydroxydopamine (6-OHDA) in the mouse
striatum producing more ROS formation [18] enhancing
iron-induced lipid peroxidation both in vitro and in vivo in
the rat striatum [19]. Other evidences suggest that motor
complications associated with sustained LD therapy are the
consequence of irregular and intermittent delivery of LD to
the brain, resulting in nonphysiologic pulsatile stimulation
of striatal DA receptors [20]. Thus, the short half-life of im-
mediate-releaseLDformulationsisthoughttobethekeyfac-
tor in the pathogenesis of motor complications [21]. Novel
treatments for PD will be successful to the extent that they
can either retard or prevent the development of these com-
plications.
It has been recently established that DAergic and sero-
toninergic nuclei in the brain are overloaded with DA fol-
lowing acute, subacute, or chronic administration of LD
[18], and the increased DA in the former nuclei can cause
production of 6-OHDA in the brain [19]. Therefore, we
hypothesized that Parkinsonian neurotoxins that generate
•OH in a DA-enriched environment would be conducive
to oxidative stress production, and melatonin may act as a
potent free radical scavenger and protect against ROS forma-
tion and the resulting DAergic neuronal death.
Melatonin is an indolamine ﬁrst reported in 1993 by Tan
et al. [22]a sa ne ﬃcient endogenous antioxidant. Melatonin
possesses several unique advantages. First, its solubility in
both lipids and water allows it to be easily distributed into
the cell. Second, its ability to cross the brain-blood barrier
allows melatonin to enter the central nervous system [23].
Melatonin has beenproven toprotect neuronal cellsfrom
neurotoxin-induced damage in a wide range of neuronal
culture systems serving as experimental models for the
study of PD (for review see [24]). In vivo experiments are
however scarce and have almost always been done in acute
experimentalmodelsofthedisease.Theseacutestudiesshow
protective eﬀects of melatonin in both the striatum DAergic
axons [25] and the midbrain neurons [26].
There is considerable evidence that pharmacological
doses of melatonin are neuroprotective in diverse models of
neurodegeneration including PD. However, there is limited
information about its eﬀects on the initial stages of neurode-
generation.
Therefore, the present study was undertaken to deter-
mine the ability of melatonin to protect striatal DAergic loss
induced by 6-OHDA in a rat model of PD, comparing the
results with LD-treated rats. The drugs were administered
fourdaysfollowinglesioning dailyforamonthatdoses suﬃ-
cient to improve physiological motor performance, and their
therapeutic or dyskinetic eﬀects were assessed using meas-
ures of abnormal involuntary movements (AIMs), skilled
forelimb use, and stepping ability. At the cellular level, the
response to the drugs was evaluated using tyrosine hydro-
xylase (TH) immunoreactivity and striatal ultrastructural
changes to compare between LD-induced AIMs and mela-
tonin-treated rats.
2.ExperimentalProcedures
The experiments were carried out in 24 male Wistar rats
weighing 180–200g at the beginning of the study. The rats
were individually housed in hanging plastic cages under
controlledlightconditions(12hlight/hdarkregime)andfed
withPurinaRatChowandwateradlibitum.Bodyweightwas
recorded daily. The experimental protocol was conduced in
accordance with the Animal Act of 1986 for Scientiﬁc Pro-
cedures. All eﬀorts were made to minimize the number of
animals used and their suﬀering.
2.1. Beam-Walking Task. Before 6-OHDA surgery, all ani-
mals were trained for one week to cross two narrow wooden
beams (6 and 12mm) into a safe platform. The beams
measured 2 meters long and were elevated to a height of 1m
above the ﬂoor with wooden supports with 15◦ inclination.
Each test session consisted of four trials in which latency to
cross the beam was recorded (we established a maximum
range of 120 seconds; if the animal did not cross at that time,
the activity was terminated and we assigned the value of 120
seconds for that evaluation). Five trials were averaged to give
a mean latency, and testing was done every week after 6-
OHDA lesion. Training and testing were performed during
the lighted portion of the cycle, at the same hour every time.
Two observers blind to the rat treatment or control status
perform all behavioral assessments.
2.2. Stereotactic Surgery and Treatments. T h er a t sw e r ea n e s -
thetized with sodium pentobarbitone (35mg/kg i.p.) and
placed in a stereotaxic apparatus. The rats were injected
with 4µL of a saline solution containing 8µg of 6-OHDA
(Sigma Chemical, USA) and 0.2mg of ascorbic acid into the
right medial forebrain bundle (n = 18), and sham lesion
w a sm a d ew i t hv e h i c l e( n = 6 (control group)). The injec-
tions were given over a 4min period with a Hamilton syringe
attached to a glass micropipette with a tip diameter of 20–
50µm. The stereotaxic coordinates were as follows: AP =
−4mmanterioroftheearbar;L = 1.4mmlateralofbregma;
V =− 7.7mm vertical of dura (according to [27]). After
recovery from the anesthesia, the animals were returned
to their home cages. Apomorphine (Sigma Chemical, USA;
0.25mg/kg i.p.) induced rotational behavior was tested two
days after lesioning. Only those animals exhibiting more
than 200 complete turns in a 30min period were used
[28]. Two days after the test, six experimental animals were
treated with 7.5-mg/kg L-DOPA (Sinemet (Carbidopa-L-
DOPA25/250)), and6weretreatedwith10mg/kgmelatonin
(Sigma Chemical, USA). The drugs were dissolved in 10mL
distilled water and given orally with an insulin syringe for
a month. The other six lesioned rats without treatment, as
well as the control animals, were kept for the same time. The
motor performance was evaluated weekly.
2.3. AIMs Rating. LD-induced AIMs were scored at day 30
according to a rat dyskinesia scale [29–31]. Rats were placedISRN Neurology 3
individually in transparent plastic cages and observed every
20th min, from 20min before to 180min after giving LD (10
monitoring periods of 1min each). Four subtypes of AIMs
were classiﬁed according to their topographic distribution
as locomotive, axial, forelimb, or orolingual (for details
see Figure 4). Enhanced manifestations of otherwise normal
behaviors, such as rearing, sniﬃng, grooming, and gnawing,
were not included in the rating. AIM severity was assessed
using the published method of Cenci et al. [29], Lee et al.
[30], and Lundblad et al. [31], which assigns a score from 0
to 4 to each of the four AIM subtypes listed above according
to the proportion of time/monitoring period during which
the AIM is present. Borderline scores, such as 0.5, 1.5, 2.5,
and 3.5, were allowed in order to increase the sensitivity of
the evaluation.
2.4. Video Recording. Performance during beam walking test
and AIM analysis was video recorded using a Panasonic
camcorder (SDR-H80 model). Representative still frames
were captured from digital video recordings with the video
editing software Final Cut Pro. Pictures were cropped and
adjusted for color and brightness contrast in Adobe Photo-
shop but were not altered in any other way.
2.5. Tissue Preparation. All rats were perfused under sodium
pentobarbital anesthesia immediately after the one-month
treatments via aorta, with saline solution followed by ﬁxative
containing 0.2% glutaraldehyde and 4% paraformaldehyde
in 0.1M phosphate buﬀer (PB). The brains were removed
and placed in ﬁxative solution for 1 hour.
2.6. TH Immunocytochemistry. C o r o n a ls e c t i o n s( 5 0 µm)
were obtained on a vibrating microtome through the mes-
encephalon for immunocytochemistry. Tyrosine hydroxylase
(ChemiconInternational,Inc.,CA,USA,1:1000)immunos-
taining with the ABC detection method (Vector Lab MI,
USA) was performed for light microscope analysis. The anal-
ysis was conducted with a computer-assisted system (Image-
Pro Plus, Media Cybernetics, L.P. Del Mar, CA, USA) con-
nected by a CCD camera to Optiphot 2 microscope (Nikon,
Japan). The number of TH-positive neurons was counted in
1500µm2 from 7SNc sections of each animal [32].
2.7. Electron Microscopy. Fragments from ipsilateral and
contralateral striata were carefully taken. After washing in
PB, the fragments were treated for 60 minutes with 1%
osmium tetroxide in PB, washed for 30 minutes in PB, dehy-
drated with graded ethanol, and ﬂat-embedded in araldite.
Ultrathin sections werecollected, counterstained with uranyl
acetate and lead citrate, and examined in a JEOL 100CX-II
electron microscope.
2.8. Ultrastructural Analysis. Synapses were deﬁned by the
presence of a clear postsynaptic density facing at least three
presynaptic vesicles. Ultrastructural analysis was performed
in 50 randomly selected synaptic endings per striatum. In
each synaptic bouton, we observed all its membrane and
organelle features, and we measured the following.
S 
B 
Figure 1: Synaptic ending (B) showing the two axes measured, es-
tablishing a synaptic contact with a dendritic spine (S).
(i) The diameter of the presynaptic bouton using two
axes, which were perpendicular to each other and
intersected at the center of the synaptic terminal
(Figure 1); the diameter was measured directly from
the electron microscope screen with a grid placed
inside the eyepiece [33].
(ii) The number of dendritic spines or dendrites as post-
synaptic targets.
(iii) Perforated synapses were identiﬁed on micrographs
of serial sections and deﬁned by the presence of a dis-
continuity in the postsynaptic density [34]. The
number of perforated synapses was determined con-
sidering the following characteristics according to
Calverley and Jones [35]: the site of the perforation
projects into the presynaptic terminal, the active
zone has one or more negatively curved components,
which are separated by a central region of the active
zone that projects into the presynaptic terminal, and
the presynaptic density is in close association to the
spine apparatus or an extension of it.
To minimize subjectivity, classiﬁcation was carried out blind
by at least two experimenters, and if distinction was unclear,
the synapse was not included in the quantiﬁcation.
2.9. Statistical Analysis. One-way ANOVA was used to ana-
lyze the number of TH-immunoreactive cells and behavioral
data. Group diﬀerences were considered statistically signiﬁ-
cant at P<0.05. When appropriate, post hoc comparisons
were made with the Tukey test. All analyses were conducted
with GraphPad Prism 5 Software.
3. Results
After 1 month, neither clinical alterations nor signiﬁcant
weight changes were detected in the experimental animals
compared with controls.4 ISRN Neurology
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Figure 2: Mean latencies to cross two narrow beams (6 and 12mm) (±SEM) before and after 6-OHDA lesion and during treatments. Note
that from the beginning of LD treatment the rats improve their motor behavior until 21 days and afterwards showed a signiﬁcant increase
in the time to transverse the beam compared to controls. In contrast, the time to cross the beam of melatonin-treated rats until day 21th
was similar to those animals with lesion and no treatment; afterwards the time was reduced drastically resembling the values of the control
group (∗P<. 001 versus control group; •P<. 001 LD-treated group versus melatonin-treated group; ANOVA test).
3.1. Beam-Walking Test. Figure 2 illustrates the mean num-
bersoftotal time tocrossthe beam.Inboth beams6mmand
12mm thick, control animals showed no signiﬁcant diﬀer-
ence in the time they took to traverse the beam. In contrast,
6-OHDA group, the animals had a very similar behavior in
both beams, taking longer to traverse them, becoming more
evident at more time after lesion; moreover lesioned animals
with no treatment had some motor features such as freezing
behavior, and, when moving, the rats were dedicated mainly
to explore the beam rather to cross it, the rats steps were
very slow compared to the control rats and several 6-OHDA-
lesioned animals could not transverse the beam in the
establishedtime.Ontheotherhand,the6-OHDA-lesioned +
LD treatment group since the beginning of treatment
showed signiﬁcant recovery of motor behavior until 21 days;
these animals took less time to traverse the beams com-
pared to the 6-OHDA-lesioned group and showed even
bettertimesthancontrolgroup,suggestinghyperactivity,but
afterwardshadasigniﬁcantincreaseinthetimetocrossanda
signiﬁcantpotentiationoffreezetime(datanotshown)com-
pared to control and 6-OHDA-lesioned + melatonin-treated
rats. The 6-OHDA-lesioned + melatonin group at 7 and
14 days evaluation showed values very similar to 6-OHDA
group without treatment, but, since 21 days, this group
demonstrated an evident motor recovery.
3.2. Abnormal Involuntary Movements (AIMs)
3.2.1. Time Course and Overall Incidence AIMs. In order to
get an overview of the development of dyskinesia in the
diﬀerent groups, we carried out the summation of all sub-
types of AIMs (axial + locomotive + limb + orolingual). As
shown in Figure 3(a), repeated measures ANOVA revealed
signiﬁcant overall diﬀerences between 6-OHDA-lesioned
and melatonin-treated groups comparing to LD-treated
group. Figure 3(b) (treatment day 30) depicts the temporal
manifestation of AIMs after a dose of LD or melatonin
resembling the time course of peak-dose dyskinesia in PD
[36, 37]. Therefore, AIM severity progressively increased
during the ﬁrst 20min posttreatment, continued elevated for
anadditional60min,andthengraduallyreturnedtobaseline
between 100 and 160min posttreatment.
3.2.2. Representation of AIM Subtypes. According to Cenci
et al. [29] and Lee et al. [30], the animals were evaluated
on four diﬀerent topographic subtypes of AIMs, which are
represented in Figure 4.D i ﬀerent AIM subtypes were main-
ly characterized among the LD-treated group (Figure 5). The
6-OHDA-lesioned animals and animals treated with me-
latonin showed no locomotive AIMs, contrasting to the
animals treated with LD that manifest this behaviorISRN Neurology 5
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Figure 3: The three groups, 6-OHDA, 6-OHDA + LD, and 6-OHDA + melatonin confer certain susceptibility to dyskinesia during the
course of the experiment, but the overall AIM severity is most pronounced in rats with 6-OHDA + LD treatment. (a) Time course of AIM
development during the chronic LD and melatonin treatments period. Values give total (locomotive + axial + orolingual + limb AIMs)
integrated AIM scores per testing session as group means ± SEM. (b) Time course of total AIM scores/monitoring period after a single
treatment of LD or melatonin (treatment day 30).
(Figure 5(a)). Animals treated with LD showed severely ab-
normal involuntary movements aﬀecting the muscles of the
neck and trunk, observed by the increase in axial AIMs score,
unlike the 6-OHDA-lesioned animals and melatonin-treated
group where these muscles were not aﬀected (Figure 5(c)).
Finally, the orolingual (Figure 5(b)) and forelimb AIMs
(Figure 5(d)) were observed in all experimental groups;
nevertheless, the score of the 6-OHDA-lesioned animals and
melatonin-treated group were very small and showed no
signiﬁcant diﬀerences compared to control animals. How-
ever, animals treated with LD showed a signiﬁcant increase
in these dyskinetic movements.
3.3. TH Immunocytochemistry. The number of TH-positive
neurons in the control group, both the ipsi and contralateral
SNc remained unchanged (x = 93 ± 1.7a n dx = 94 ±
1.9, resp.). In contrast, we found an important loss of TH-
positive neurons in the SNc of 6-OHDA lesioned animals in
both ipsilateral (x = 5±1.6) and contralateral (x = 73±1.9)
SNc compared to controls as shown in Figures 6 and 7;
likewise, LD-treated rats (x = 59 ± 1.0a n d6± 2.0c o n -
tralateral and ipsilateral, resp.) and melatonin-treated rats
(x = 77 ± 0.48 contralateral and x = 10.2 ± 0.218 ipsilat-
eral SNc) show signiﬁcant loss of TH-positive cells; however,
melatonin-treated animals exhibited less neuronal loss com-
pared to the group treated with LD.
3.4. Electron Microscopy
3.4.1. Diameters of Synaptic Endings. Control rats did not
show any diﬀerences between both striata synaptic end-
ings diameter and neuropile alterations after sham surgery
(Figures 8and9(A)).AsshowninFigure 8,thesynapticend-
ings of the control group major axis presented an average of
696.8±9.4nmonthecontralateralstriatumand700±9.6nm
ontheipsilateralone;theminoraxismeanwas474.9±9.6nm
on the contralateral and 477.0+9 .6µm2 on the ipsilateral
striatum. The 6-OHDA-lesioned group showed an evident
increase in the size of synaptic boutons (x = 980.3 ± 16.13
and1379.7±18nmminorandmajoraxis,respectively,ofthe
ipsilateral striatum); the same pattern was observed in the 6-
OHDA + LD-treated group (x = 966.0±12.10 and 1340.0±
13.20nm minor axis and major axis of the ipsilateral side,
resp.); there were statistically signiﬁcant diﬀerences in both
groups comparing to control group (Figure 8). 6-OHDA +
melatonin-treated group showed fewer presynaptic buttons
with edema (x = 778.7 ± 11.05nm and 1115.30 ± 11.00nm
minor and major axis of the ipsilateral side, resp.), showing
statistically signiﬁcant diﬀerences comparing to 6-OHDA +
LD and lesioned untreated groups. The contralateral (non-
lesioned side) of all experimental groups (6-OHDA, 6-
OHDA + L-DOPA and 6-OHDA + melatonin) showed no
statisticallysigniﬁcantdiﬀerencescomparedtocontrolgroup
(Figure 8).
3.4.2. Postsynaptic Target. When analyzing the postsynaptic
structure(spineordendrite)withwhichsynapticcontactwas
established, we note that in control group prevailed synaptic
contacts with dendritic spines (Figures 9(A) and 10) show an
average of 28 ±1.0 for the contralateral side and 27 ±1.9f o r
the ipsilateral one, unlike 6-OHDA group (x = 20±1.6) and
6-OHDA+LD-treatedgroup(x = 21±1.8),wheretherewas
an important decrease in the number of synaptic contacts
established with dendritic spines in ipsilateral striatum6 ISRN Neurology
(a)
(b)
(c)
(d)
Figure 4: Sequences of video recordings from rats aﬀected by locomotive (a), axial (b) orolingual (c), and forelimb AIMs (d). Locomotive
AIMs (a) comprise circular movement towards the contralateral side to the lesion. Only locomotive movements involving all four limbs are
rated under this AIM category. The sequence in (b) shows a torsion movement of the neck and upper trunk towards the contralateral side to
the lesion. Body torsion is maximally severe (>90◦), causing the rat to lose equilibrium. Orolingual AIMs (c) include opening and closing of
the jaws and tongue protrusion towards the side contralateral to the lesion (arrow). A black circle in (d) highlights purposeless up and down
translocation of the Parkinsonian (right) forelimb.
(Figures 9(B), 9(C), and 10); there were signiﬁcant diﬀer-
ences comparing to control group and the group treated
with melatonin; the latter presented similar number of syn-
aptic contacts with dendritic spines than the control group
(Figures 9(D) and 10).
3.4.3. Perforated Synapses. Figure 11 depicts the number of
perforated synaptic contacts in the diﬀerent groups; the con-
trol group had a mean of 5 ± 1.7 contralateral and 4 ± 1.9
in the ipsilateral striata, in contrast; all experimental groups
showed an increase in the number of perforated contacts inISRN Neurology 7
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Figure 5: Integrated AIM scores were generated separately for locomotive (a), orolingual (b), axial (c), and forelimb (d) AIMs using data
fromday30ofchronictreatments.NotethatanimalstreatedwithmelatonindidnotdeveloplocomotiveAIMsandaxialrotation(∗P<0.005
LD-treated group versus 6-OHDA-lesioned and melatonin-treated groups).8 ISRN Neurology
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Figure 6: TH-immunoreactive cell counts from the SNc. The data
arepresentedasthemean ±SEM.Astatisticallysigniﬁcantdecrease
in TH-immunoreactive cells was detected in both ipsilateral (I) and
contralateral (C) SNc in the three experimental groups (∗P<0.05
versus control group; •P<0.05 between melatonin and 6-OHDA
and LD-treated groups; ANOVA test).
bothstriata,becomingmoreevidentintheipsilateralside;we
found signiﬁcant diﬀerences compared to the control group
(Figures 9(D) and 11).
4. Discussion
The ﬁndings of the present study demonstrated that chron-
ic oral administration of melatonin corrected a hemi-
Parkinson’sconditioninratscausedbyintramedialforebrain
bundle application of the neurotoxin 6-OHDA. melatonin-
treated animals perform better in the motor tasks and had
no dyskinetic alterations compared to LD-treated rats. At the
cellular level, we found that melatonin-treated rats showed
more TH-positive neurons and their striatal ultrastructure
was well preserved, which probably led to the functional re-
covery.
4.1. Motor Behavior. Our results show that 6-OHDA-lesion-
ed animals displayed decreased motor coordination, becom-
ing more evident over time following lesion. This ﬁnding is
consistent with the results of Allbut and Henderson [38],
who demonstrate that rats unilaterally lesioned with 6-
OHDA in the medial forebrain bundle presented motor be-
havior alterations when evaluated on a beam-walking test;
theyobserved thatthetime theratstook totraversethebeam
wasdrasticallyincreasedcomparedtocontrolgroup;animals
also showed rigidity and restraint in their movements when
walking the beam. Some rats roamed the beam and stopped
and then restarted or just stand still, which is analogous to
the behaviors observed in patients with PD. Also, Truong
et al. [39] conducted a study in rats unilaterally lesioned
with 6-OHDA at diﬀerent doses and subsequently evaluated
motor behavior in a wooden beam. The animals showed
a travel time of about 1 minute at 2 and 4 weeks after
Control
6-OHDA
6-OHDA + LD
6-OHDA + melatonin
Figure 7: Representative TH-immunostained from coronal sec-
tions containing the SNc of control, 6-OHDA-lesioned, 6-OHDA-
lesioned + LD and 6-OHDA-lesioned + melatonin-treated rats.
Note the profound cell loss in the ipsilateral SNc in the three
experimental groups, being more evident in the 6-OHDA and
LD treated ones; also, the contralateral SNc of melatonin-treated
rats lost fewer neurons than the other two experimental groups
(magniﬁcation 4×).
lesion, while the control group showed a travel time of 0.2
minutes, concluding that changes in motor performance are
correlated with the loss of DAergic cells.
As described in our results, animal treated with LD
showed improvement to traverse the beam until 21 days,
but after 28 days the treatment was no longer able to reduce
themotoralterationsinducedby6-OHDA-lesionOurresults
also show that animals with DA denervation reproduce
dyskinetic motor eﬀects when treated with therapeutical
doses of LD. As we mentioned previously, LD treatment is
themosteﬀectivedrugforPDtreatment,sincenootherdrug
matches its ability to suppress the symptoms. However, after
chronic treatment, 30 to 80% of patients develop side eﬀects
such as dyskinesias that become more disabling than the
diseaseitself[40].InthisregardRajputetal.[41]standoutin
their review that patients who received LD, about two-thirds,
had beneﬁts within the ﬁrst three to six months of treatment,
but after a while show a clear deterioration accompanied
by a constant increased complications, such as changes in
threshold and AIMs [42]. It has also been reported that
patients who develop dyskinesias due to prolonged use of LD
are characterized by involuntary and uncontrollable chaotic
movements of the mouth, cheeks, arms, and legs [43, 44];
these dyskinesias may be considered a negative reaction of
brain plasticity in response to the time of disease progression
a n dp r o l o n g e du s eo fL D[ 44, 45].ISRN Neurology 9
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Figure 8: Synaptic ending mean diameter in ipsilateral (I) and contralateral (C) striata after stereotactic surgery and treatments, major and
minor axes (∗P<0.05 versus control group; •P<0.05 between melatonin and 6-OHDA and LD-treated groups; ANOVA test).
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Figure 9: Electron micrographs from control group rat striatum neuropile (A); 6-OHDA-lesioned ipsilateral striatum (B); 6-OHDA +
LD treated rat ipsilateral striatum (C); 6-OHDA + melatonin-treated rat ipsilateral striatum (D). (A) In control group, the mean size of
t h es y n a p t i cb u t t o n s( b )w a s7 0 0× 696nm, and the predominant Postsynaptic target was the dendritic spines (s); it can be observed that
the neuropile is well preserved. (B) This image shows a swollen synaptic button (b) establishing a synaptic contact with a dendritic spine
(s), altered mitochondria (arrowhead), and some vacuoles (∗) within neuropile. (C) This image demonstrates three edematous presynaptic
endings(b)oftheLD-treatedipsilateralstriatumestablishingthreesynapticcontacts,onewithadendriticspinewithdilatedspineapparatus
(sa), and two with a dendrite (d). Note the altered mitochondria (arrow heads) and neuropile vacuoles (∗). (D) An increase in the presence
of perforated synaptic contacts was notorious in striata of the three experimental groups (arrow). Note that the neuropile of the melatonin-
treatedgroup iswell preserved, similar tocontrolgroup neuropile. (b)Synaptic bouton,(sa)spineapparatus, (s)dendritic spine.Bar 0.2µm.10 ISRN Neurology
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Figure 10: This graph shows the average number of synaptic bou-
tons that established synaptic contact with dendritic spine in the
ipsilateral and contralateral striata of the four analyzed groups
(∗P<0.005 versus control group and melatonin-treated group;
ANOVA test).
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Figure 11: This graph shows the average of the total number of
perforated synapses in the ipsilateral and contralateral striata of
the four analyzed groups (∗P<0.005 versus control group and
melatonin-treated group; ANOVA test).
The mechanism by which LD induces motor complica-
tions has not been established, but several theories have been
proposed: (A) the ﬂuctuations may occur due to deﬁciencies
in the synthesis and storage of DA in DAergic terminals
[40]; (B) the DA transporter system, which represents a
major mechanism by which DA is removed from the synapse
(which is a crucial element involved in the regulation of
DAergic transmission) [46], is altered by prolonged LD
treatment [47]; (C) it seems that LD produce oxidative
damage perpetuating cell death [14–17] enhancing iron-in-
duced lipid peroxidation [19]. Other evidences suggest that
motor complications associated with sustained LD therapy
are a result of irregular and intermittent delivery of LD to
the brain, resulting in nonphysiologic pulsatile stimulation
of striatal dopamine receptors [20].
On the other hand, animals treated with melatonin
showed a motor performance very similar to 6-OHDA-
lesioned group at 7 to 14 days; afterwards the animals im-
proved; this became more evident at 28 days after lesion.
We consider that melatonin-treated animals probably do not
improve their motor behavior at the start of treatment, as
the neurotoxin is highly aggressive and causes some cells no
longer functional (i.e., discontinue producing DA) without
necessarily inducing death [48], and therefore display a
motor imbalance very similar to 6-OHDA-lesioned group;
thus it is feasible to think that melatonin treatment trigger
diﬀerent signaling pathways to enhance the mechanism
against ROS produced by 6-OHDA; so after some time it is
possible that the cell is able to recover its DAergic pheno-
type, producing a modulatory eﬀect reﬂected in functional
recovery. It has also been reported that elevated ROS par-
ticipate in 6-OHDA neurotoxicity; this has been evidenced
by the reduction in brain GSH levels and in the loss of SOD
activity[49].Melatoninstimulatesantioxidantenzymessuch
as SOD, GPX, and glutathione reductase [50]. Singh et al.
[51] demonstrated that systemic administration of melato-
ninprotectedstriatalDAergicneuronsagainst6-OHDAneu-
rotoxicity in the rat. The eﬀect was accompanied by a sig-
niﬁcant recovery in motor behavior tests.
In this regard Singh et al. [51] have reported that animals
pretreated systemically with melatonin and subsequently
lesioned with 6-OHDA and treated with melatonin for
a period of 7 days showed a decrease in the number
of apomorphine-induced rotations, improved posture, and
slownessofmovementcomparedto6-OHDA-lesionedtreat-
ed with vehicle solution group. These results demonstrate
that melatonin treatment may have beneﬁcial eﬀects for the
treatment of PD. Furthermore, Hamdi [52]c o n d u c t e da
study in animals where he administered melatonin in drink-
ing water and found that the striatum had a higher aﬃnity to
D2 receptor, while the number of receptors did not change.
The mechanism by which melatonin increases the aﬃnity
of D2 receptors is unknown, but the author suggests that
this eﬀect may be produced through conformational changes
in the receptor-binding site. This mechanism may in-
volve a functional alteration by a direct or indirect eﬀect of
melatonin on one or more levels that is, gene expression and
receptor proteins synthesis; thus melatonin may represent a
modulatory inﬂuence on the DAergic system [53].
4.2. TH Immunocytochemistry. We observed a severe de-
crease of TH-positive cells after depleting the nigrostriatal
pathway; our results agree with Damier et al. [54] who found
that PD patients showed a reduction of DAergic neurons up
to95%dependingonthetimeofclinicalevolution.Likewise,
it has been demonstrated that the medial forebrain bundle
unilateral lesion reduces 98% the SNc ipsilateral num-
ber of TH-immunoreactive neurons [38, 55]. We found that
6-OHDA-lesioned and 6-OHDA + LD-treated groups dis-
played a very similar pattern, showing a dramatic loss of TH-
immunoreactive neurons. The cell loss after LD treatment
may have been because LD is converted to DA by theISRN Neurology 11
enzyme AADC and thus raises the levels of DA in the
striatum [56], this in consequence may act as a cell death
perpetrator, since there is evidence that suggests that large
amounts of DA, in addition to serving as a neurotransmitter,
can act as a neurotoxin. It has been found in culture cells
e x p o s e dt oh i g hl e v e l so fD At h a tD Ai sa b l et op r o d u c e
apoptotic neuronal death [57], decrease levels of GSH, and
increase intracellular Ca2+; these eﬀects of DA oxidation in
cellular physiology in vivo may occur under conditions of
oxidative stress, increasing the vulnerability of DAergic neu-
rons to degeneration [58]. Furthermore, Maharaj et al. [19]
demonstrate that LD might accelerate the rate of SNc degen-
eration because it undergoes oxidative metabolism to form
6-OHDA.
About the data obtained after melatonin treatment, we
observedthatthisindolaminepartiallypreventsSNcDAergic
cell damage produced by 6-OHDA lesion. 6-OHDA toxicity
is based on direct inhibition of complex I of the electron
transport chain in the mitochondria [59]. Inhibition of this
complex has also been reported in the SNc of patients suﬀer-
ingPD.Thisinhibitioncausesenergydepletionandincreases
free radical concentration in the mitochondria [60]. In the
present work, for melatonin-treated group, although the cell
percentage decreases (comparing ipsilateral to contralateral
sides), the loss was less severe than that detected in 6-
OHDA-lesioned and LD-treated rats. The antioxidant eﬀects
of melatonin and its protective eﬀects against the uncou-
pling of the electron transport chain of several toxins in
the mitochondria have been well summarized by Acu˜ na-
Castroviejo et al. [61] .T h e s ed a t au r g eu st ou n d e r t a k e
further studies based on this hypothesis. In vivo studies with
melatonin in experimental models of PD are however scarce.
Acu˜ na-Castroviejo et al. [25] found that melatonin prevent-
ed an increase in lipid peroxidation and a decrease in
TH immunoreactivity in the striatum after a single dose
of MPTP, arguing that melatonin was able to prevent the
damage caused by this drug in the striatal dopaminergic
axons. Ortiz et al. [26] reported, using DNA electrophoresis,
apoptosis of midbrain neurons induced by a single dose
of MPTP. Melatonin also prevented both cell damage and
DNA fragmentation. Also, melatonin was able to counteract
the decrease in striatal TH immunoreactivity and the loss
of complex I activity produced in rats after acute 6-OHDA
administration [62, 63]. Similarly, Kim et al. [64] showed
that melatonin treatment rescues nigrostriatal dopaminergic
neurons from cell death in 6-OHDA-lesioned rats suggesting
that this beneﬁcial eﬀect was a consequence of the potent
antioxidative action of melatonin. Thus, melatonin has been
reported to protect against 6-OHDA [63], MPTP [25],
and MPP+ lesions [65]. However, it should be emphasized
that these melatonin-induced eﬀects have been traditionally
discussed in the context of the eﬃcient free radical scavenger
and antioxidant properties of this pineal hormone (for a
review see Reiter [24]). Nevertheless, our data show a stim-
ulating eﬀect of melatonin over TH-immunoreactivity sug-
gesting a role over the nigrostriatal DAergic system. In fact,
melatonin has been shown to regulate striatal dopaminergic
activity and block LD-induced dyskinesias [66]. As we men-
tioned above, it is therefore plausible to assume a role for
melatonin as a neuromodulator in the nigrostriatal DAergic
system [67]; however, further analyses are needed to clarify
this point.
4.3. Electron Microscopy. The ultrastructural analysis of the
striatum neuropile after unilateral 6-OHDA lesion of the
medial forebrain bundle of rats and after LD treatment re-
vealed that this neurotoxin induces derangement of the ipsi-
lateral striatum neuropile characterized by (1) edema of the
presynaptic buttons, (2) changes on the postsynaptic targets,
and (3) increase in the number of perforated synapses, alter-
ations that improved with melatonin treatment.
The present analysis conﬁrms previous observations [33,
68–70], concerning to the fact that DA depletion of the
nigrostriatal pathway causes an increment in the size of
synaptic buttons. The authors assume that this swelling is
due to an inherent degenerative process caused by 6-OHDA
lesion, because they saw this increment in size in almost all
synaptic endings that were measured. Here, we observe that
melatonin treatment prevented synaptic ending swelling.
Biochemical abnormalities relevant to the pathogenesis of
PD include mitochondrial dysfunction, free radical-mediat-
ed damage, excitotoxicity, and inﬂammation [71, 72]. About
the anti-inﬂammatory eﬀects of melatonin, the most im-
portant feature is its inhibition of iNOS expression [73]. me-
latonin administration prevented mitochondrial iNOS in-
duction in sepsis and in MPTP-treated mice, avoiding res-
piratory chain dysfunction and preserving ATP production
[61, 74–76]. The indolamine also increases the activity of the
respiratory complexes, counteracts the oxidative stress, and
maintains the mitochondrial GSH pool under diﬀerent ex-
perimental conditions both in vivo and in vitro [77]. These
antioxidant and anti-inﬂammatory properties of melatonin
are relevant in mitochondrial physiology, and they may play
a neuroprotective role in PD [71].
Concerning dendritic spine loss, Roberts and DiFiglia
[78],Inghametal.[68],Pickeletal.[69],Stephensetal.[79],
and Avila-Costa et al. [33, 70] found that the proportion of
axospinous synapses was signiﬁcantly reduced in the ipsi-
lateralstriatum of the 6-OHDA lesioned rats, type of synapse
that also decrease in caudate nucleus of PD patients [80–
82]. Here we found an evident loss of dendritic spines in
6OHDA-lesioned and LD-treated rats. Schuster et al. [83]
reported that, after 6-OHDA lesion and LD treatment, the
rats presented a marked loss of dendritic spines in the
lesionedstriatum,suggestingthatthepreventionofdendritic
spine loss is crucial to impede AIMs. However, it is possible
that the role for spine loss after DA depletion could be
adaptive and might prevent degeneration of striatal neurons
from a sustained and excessive glutamatergic input in the
absence of endogenous DAergic control of the excitatory
transmission [83]. There is no doubt that the spine loss
response is adaptive because preventing the elevation in
dendritic excitability signiﬁcantly reduces spine loss [84,
85]. Nevertheless, melatonin treatment, here, prevented the
dendritic spine loss, a fact that is related to the greater
number of TH-positive cells and the functional recovery,
making melatoninaplausiblecandidatetoavoiddiseasepro-
gression.12 ISRN Neurology
Ontheotherhand,previousreportsstandoutthatnigro-
striatal synaptic terminals most commonly form contacts
with dendritic spines and less commonly with the somata
or dendrites of striatal neurons [86–91]. Following 6-OHDA
lesioning, the number of distal dendrite and spine contacts
decrease, and consequently there are a greater proportion of
more proximal dendrite and soma contacts [91, 92]. More
recently, Reynolds et al. [93] described how stimulation of
the SNc induced potentiation of the glutamatergic synapses
between the cortex and the striatum that was dependent on
activation of DA receptors. The corticostriatal glutamatergic
ﬁbres synapse onto the heads of dendritic spines of the stri-
atal neurons, whereas the SNc terminals normally synapse
onto the spine necks. As more proximal synapses are be-
lievedtoelicitgreaterphysiologicalchangesinthetargetneu-
rons than distal synapses [69], the more proximal site of
termination of the reinnervated DA terminals could en-
hance the eﬃciency of DA intensiﬁcation of glutamatergic
transmission. Indeed, Picconi [94] described that plasticity
at the cortical projection onto spiny neurons was altered by
selective DA receptor blockade and following DA denerva-
tion but restored by LD therapy, at least at the start of treat-
ment[94–96].Otherauthorshavenotedthat,followingneu-
roleptic treatment, there is persistent modiﬁcation in den-
dritesandspines,especiallyintheventralstriatum.Aslesion-
ing and LD therapy both produce damage [97], it is possible
that this alteration provides the drive for the synaptic
remodeling described here and elsewhere [98–100], such as
the increment in the number of perforated synapses [34]. We
speculate that the altered morphology and function of these
terminals not only reﬂect mechanisms that may compensate
for the loss of nigral neurons but may also be important
in understanding the molecular processes underlying the
dyskinesia induced by LD treatment.
Finally, the incremented number of perforated synapses
in the three experimental groups is in agreement with
other authors who reported an important proliferation of
perforated synapses following harming circumstances, hip-
pocampal kindling [101], unilateral lesion of the entorhinal
cortex [102], and other brain lesions [103]. These authors
suggest that the perforations may function to increase the
perimeter surface of the postsynaptic density and also the
eﬃciency of neurotransmission. Furthermore, this kind of
synapses are intermediate structures in an ongoing cycle
of the breakdown and replacement of synapses that are
lost because of a speciﬁc lesion, transmission changes, or
ageing process [104]. In this way, See et al. [105]d e m o n -
strate that after chronic neuroleptic treatment, which in-
creases the DAergic binding sites, there was a signiﬁcant in-
crementinthenumberofperforatedsynapses.Inthatreport,
the authors found an important proliferation in perforat-
ed synapses after the lesion, maybe as a consequence of the
postsynaptic supersensitivity of the DAergic receptors re-
ported by Ungerstedt [106], which in turn induces synaptic
plasticity, increasing the length of the postsynaptic density
[34]. Therefore, selective synaptic changes in shape and
function are possibly signs of excitotoxic injury, as ob-
served in diverse neurological diseases and neurodegener-
ative disorders. Elucidating mechanisms that mediate the
synaptic alterations under pathological conditions may be
offundamentalimportancetounderstandingmechanismsof
neuronal injury. In spite of many new ﬁndings, there are still
various questions to be answered and further experiments to
be done. The mechanisms of synaptic plasticity are still not
completely clear: the role of retrograde messengers, details in
the molecular cascades leading to gene expression and new
protein synthesis or to growth of new synapses, ﬁnding the
more accurate causal connection between plasticity and vari-
ousformsoflearning,memory,andcell.Theuseofregulated
and anatomically restricted genetic modiﬁcation, combined
with morphologic analysis, should provide a powerful set of
tools for elucidating synaptic plasticity mechanisms damage
[107].
In conclusion, the data described in the present study
provides further evidence that melatonin acts as a DA regu-
lator impeding partially the DAergic cell death by means
of preservation of the striatal neuropile and the dendritic
spines, promoting functional recovery, since melatonin-
treated rats displayed better motor performance and no
dyskinetic alterations, compared to LD-treated rats.
Melatonin displays an important antioxidant property
based on its ability to function as a free radical scavenge.
Particularly, in contrast to conventional antioxidants, mela-
tonin can rapidly cross the blood-brain barrier after systemic
administration. This unique character enables melatonin to
directly reach the neuronal compartment [23]. At this point,
we have to focus on early, long-term, preventive admin-
istrationofmelatonin.Basedonpreviousandcurrentresults,
melatonin is more likely the complementary and alternative
therapy.
It is important to stand out that levels of melatonin tend
to decrease with age in contrast to the increased incidence
of neurodegenerative diseases. Aging and neurodegenerative
diseases have been proposed as a consequence of the
imbalance (physiological or toxin-induced) between oxidant
production by the organism and its antioxidant defense sys-
tem. Other constituents of this antioxidant system have not
been found to decrease with age, melatonin being the only
one matching this age-related pattern. This points to an in-
crease in free radicals which are endogenously or exoge-
nously produced. The protective eﬀect of melatonin demon-
strated in abundant cell culture experiments, together with
the in vivo protection against 6-OHDA and MPTP-induced
cell damage, makes melatonin a plausible candidate in
the prevention of the appearance of these diseases and
gives a clue to its use as a treatment to avoid disease
progression [60]. Consequently, melatonin administration
combines antioxidant capacity along with a tissue-speciﬁc
TH-inducing eﬀect, which could be beneﬁcial for treating
PD.
Acknowledgments
The authors acknowledge Jesus Espinosa Villanueva and
Patricia Aley Medina for their excellent photographical
and technical assistance. This paper was supported by
PAPCA-Iztacala UNAM no. 30-2010-2011, PAPIIT-DGAPA
IN220111, and CONACyT-SNI–118320. Authors also thankISRN Neurology 13
the Posgrado en Ciencias Biol´ ogicas of Universidad Nacional
Aut´ onoma de M´ exico.
References
[1] T. L. Perry and V. W. Yong, “Idiopathic Parkinson’s disease,
progressive supranuclear palsy and glutathione metabolism
in the substantia nigra of patients,” Neuroscience Letters, vol.
67, no. 3, pp. 269–274, 1986.
[ 2 ]H .S a g g u ,J .C o o k s e y ,D .D e x t e re ta l . ,“ As e l e c t i v ei n c r e a s e
in particulate superoxide dismutase activity in parkinsonian
substantia nigra,” Journal of Neurochemistry, vol. 53, no. 3,
pp. 692–697, 1989.
[3] D. T. Dexter, F. R. Wells, A. J. Lees et al., “Increased nigral
iron content and alterations in other metal ions occurring in
brain in Parkinson’s disease,” Journal of Neurochemistry, vol.
52, no. 6, pp. 1830–1836, 1989.
[4] A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R.
Stadtman, and Y. Mizuno, “Immunohistochemical detection
of 4-hydroxynonenal protein adducts in Parkinson disease,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 93, no. 7, pp. 2696–2701, 1996.
[ 5 ]Z .I .A l a m ,S .E .D a n i e l ,A .J .L e e s ,D .C .M a r s d e n ,P .J e n n e r ,
and B. Halliwell, “A generalised increase in protein carbonyls
in the brain in Parkinson’s but not incidental Lewy body
disease,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1326–
1329, 1997.
[6] J. T. Coyle and P. Puttfarcken, “Oxidative stress, glutamate,
and neurodegenerative disorders,” Science, vol. 262, no. 5134,
pp. 689–695, 1993.
[7] M. Ebadi, S. K. Srinivasan, and M. D. Baxi, “Oxidative stress
and antioxidant therapy in Parkinson’s disease,” Progress in
Neurobiology, vol. 48, no. 1, pp. 1–19, 1996.
[ 8 ]A .N .B a s m a ,E .J .M o r r i s ,W .J .N i c k l a s ,a n dH .M .G e l l e r ,
“L-DOPA cytotoxicity to PC12 cells in culture is via its
autoxidation,” Journal of Neurochemistry,v o l .6 4 ,n o .2 ,p p .
825–832, 1995.
[9] A. A. Corona-Morales, A. Castell, A. Escobar, R. Drucker-
Col´ ın, and L. Zhang, “Fullerene C60 and ascorbic acid pro-
tectculturedchromaﬃncellsagainstlevodopatoxicity,”Jour-
nalofNeuroscienceResearch,vol.71,no.1,pp.121–126,2003.
[10] J. E. Ahlskog and M. D. Muenter, “Frequency of levodopa-
related dyskinesias and motor ﬂuctuations as estimated from
thecumulativeliterature,”MovementDisorders,vol.16,no.3,
pp. 448–458, 2001.
[11] J. Jankovic, “Motor ﬂuctuations and dyskinesias in Parkin-
son’s disease: clinical manifestations,” Movement Disorders,
vol. 20, no. 11, pp. S11–S16, 2005.
[12] A.Schrag, Y.Ben-Shlomo,and N.Quinn,“Howcommon are
complications of Parkinson’s disease?” Journal of Neurology,
vol. 249, no. 4, pp. 419–423, 2002.
[13] J. A. Obeso, C. W. Olanow, and J. G. Nutt, “Levodopa
motor complications in Parkinson’s disease,” Trends in Neu-
rosciences, vol. 23, no. 10, pp. S2–S7, 2000.
[14] J. W. Miller, J. Selhub, and J. A. Joseph, “Oxidative damage
caused by free radicals produced during catecholamine
autoxidation: protective eﬀects of O-methylation and mela-
tonin,” Free Radical Biology and Medicine,v o l .2 1 ,n o .2 ,p p .
241–249, 1996.
[15] C. W. Olanow, Y. Agid, Y. Mizuno et al., “Levodopa in
the treatment of Parkinson’s disease: current controversies,”
Movement Disorders, vol. 19, no. 9, pp. 997–1005, 2004.
[16] M. Lee, V. Tazzari, D. Giustarini et al., “Eﬀects of hydrogen
sulﬁde-releasing L-DOPA derivatives on glial activation:
potential for treating Parkinson disease,” Journal of Biological
Chemistry, vol. 285, no. 23, pp. 17318–17328, 2010.
[17] E.Milusheva,M.Baranyi,E.Kormos,Z.Hracsk´ o,E.Sylvester
Vizi, and B. Sperl´ agh, “The eﬀect of antiparkinsonian drugs
on oxidative stress induced pathological [3H]dopamine
eﬄux after in vitro rotenone exposure in rat striatal slices,”
Neuropharmacology, vol. 58, no. 4-5, pp. 816–825, 2010.
[18] A. Borah and K. P. Mohanakumar, “Melatonin inhibits 6-
hydroxydopamine production in the brain to protect against
experimental parkinsonism in rodents,” Journal of Pineal
Research, vol. 47, no. 4, pp. 293–300, 2009.
[19] H. Maharaj, D. Sukhdev Maharaj, M. Scheepers, R.
Mokokong, and S. Daya, “L-DOPA administration enhances
6-hydroxydopamine generation,” Brain Research, vol. 1063,
no. 2, pp. 180–186, 2005.
[20] W. Poewe, A. Antonini, J. C. Zijlmans, P. R. Burkhard, and
F. Vingerhoets, “Levodopa in the treatment of Parkinson’s
disease: an old drug still going strong,” Journal of Clinical
Interventions in Aging, vol. 5, pp. 229–238, 2010.
[21] C. W. Olanow, “The scientiﬁc basis for the current treatment
of Parkinson’s disease,” Annual Review of Medicine, vol. 55,
pp. 41–60, 2004.
[22] D. X. Tan, L. C. Manchester, R. J. Reiter et al., “A novel mela-
tonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of
in vivo hydroxyl radical generation,” Biochemical and Bio-
physical Research Communications, vol. 253, no. 3, pp. 614–
620, 1998.
[ 2 3 ] R .J .R e i t e r ,J .C a b r e r a ,R .M .S a i n z ,J .C .M a y o ,L .C .M a n c h -
ester, and D. X. Tan, “Melatonin as a pharmacological agent
againstneuronallossinexperimentalmodelsofHuntington’s
disease, Alzheimer’s disease and Parkinsonism,” Annals of the
New York Academy of Sciences, vol. 890, pp. 471–485, 1999.
[24] R. J. Reiter, “Oxidative damage in the central nervous system:
protection by melatonin,” Progress in Neurobiology, vol. 56,
no. 3, pp. 359–384, 1998.
[25] D. Acu˜ n a - C a s t r o v i e j o ,A .C o t o - M o n t e s ,M .G .M o n t i ,G .
G. Ortiz, and R. J. Reiter, “Melatonin is protective against
MPTP-induced striatal and hippocampal lesions,” Life Sci-
ences, vol. 60, no. 2, pp. 23–29, 1996.
[26] G. G. Ortiz, M. Elena Crespo-L´ opez, C. Mor´ an-Moguel, J.
J. Garc´ ı a ,R .J .R e i t e r ,a n dD .A c u ˜ na-Castroviejo, “Protective
role of melatonin against MPTP-induced mouse brain cell
DNAfragmentationandapoptosisinvivo,”Neuroendocrinol-
ogy Letters, vol. 22, no. 2, pp. 101–108, 2001.
[27] G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Co-
ordinates, Academic Press, New York, NY, USA, 2nd edition,
1986.
[28] U. Ungerstedt and G. W. Arbuthnott, “Quantitative record-
ing of rotational behavior in rats after 6-hydroxy-dopamine
lesionsofthenigrostriataldopaminesystem,”BrainResearch,
vol. 24, no. 3, pp. 485–493, 1970.
[29] M. A. Cenci, C. S. Lee, and A. Bj¨ orklund, “L-DOPA-induced
dyskinesia in the rat is associated with striatal overexpression
of prodynorphin- and glutamic acid decarboxylase mRNA,”
European Journal of Neuroscience, vol. 10, no. 8, pp. 2694–
2706, 1998.
[30] C. S. Lee, M. A. Cenci, M. Schulzer, and A. Bj¨ orklund, “Em-
bryonic ventral mesencephalic grafts improve levodopa-in-
duceddyskinesiainaratmodelofParkinson’sdisease,”Brain,
vol. 123, no. 7, pp. 1365–1379, 2000.
[31] M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N.
Wierup, and M. A. Cenci Nilsson, “Pharmacological vali-
dation of behavioural measures of akinesia and dyskinesia
in a rat model of Parkinson’s disease,” European Journal of
Neuroscience, vol. 15, no. 1, pp. 120–132, 2002.14 ISRN Neurology
[32] M. R. Avila-Costa, E. Montiel Flores, L. Colin-Barenque et
al., “Nigrostriatal modiﬁcations after vanadium inhalation:
an immunocytochemical and cytological approach,” Neuro-
chemical Research, vol. 29, no. 7, pp. 1365–1369, 2004.
[33] M. R. Avila-Costa, L. Col´ ın-Barenque, E. Montiel-Flores
et al., “Bromocriptine treatment in a Murine Parkinson’s
model:ultrastructuralevaluationafterdopaminergicdeaﬀer-
entation,” International Journal of Neuroscience, vol. 115, no.
6, pp. 851–859, 2005.
[34] M. R. Avila-Costa, L. Col´ ın-Barenque, P. Aley-Medina et
al., “Bilateral increase of perforated synapses after unilateral
dopamine depletion,” International Journal of Neuroscience,
vol. 115, no. 1, pp. 79–86, 2005.
[35] R. K. S. Calverley and D. G. Jones, “A serial-section study
of perforated synapses in rat neocortex,” Cell and Tissue Re-
search, vol. 247, no. 3, pp. 565–572, 1987.
[36] J. G. Nutt, “Levodopa-induced dyskinesia: review, observa-
tions, and speculations,” Neurology, vol. 40, no. 2, pp. 340–
345, 1990.
[37] S. Fahn, “The spectrum of levodopa-induced dyskinesias,”
Annals of Neurology, vol. 47, no. 4, supplement 1, pp. S2–S11,
2000.
[38] H. N. Allbutt and J. M. Henderson, “Use of the narrow beam
test in the rat, 6-hydroxydopamine model of Parkinson’s
disease,” Journal of Neuroscience Methods, vol. 159, no. 2, pp.
195–202, 2007.
[39] L. Truong, H. Allbutt, M. Kassiou, and J. M. Henderson,
“Developing a preclinical model of Parkinson’s disease: a
study of behaviour in rats with graded 6-OHDA lesions,”
Behavioural Brain Research, vol. 169, no. 1, pp. 1–9, 2006.
[ 4 0 ]P .J .B l a n c h e t ,R .B o u c h e r ,a n dP .J .B e d a r d ,“ E x c i t o t o x i cl a t -
eral pallidotomy does not relieve L-DOPA-induced dyskine-
sia in MPTP parkinsonian monkeys,” Brain Research, vol.
650, no. 1, pp. 32–39, 1994.
[ 4 1 ] A .H .R a j p u t ,M .E .F e n t o n ,T .D iP a o l o ,H .S i t t e ,C .P i ﬂ ,a n d
O. Hornykiewicz, “Human brain dopamine metabolism in
levodopa-induced dyskinesia and wearing-oﬀ,” Parkinsonism
and Related Disorders, vol. 10, no. 4, pp. 221–226, 2004.
[42] N. B. Mercuri and G. Bernardi, “The ‘magic’ of L-dopa: why
is it the gold standard Parkinson’s disease therapy?” Trends in
Pharmacological Sciences, vol. 26, no. 7, pp. 341–344, 2005.
[43] P. J. Blanchet, S. Konitsiotis, E. R. Whittemore, Z. L. Zhou,
R. M. Woodward, and T. N. Chase, “Diﬀering eﬀects of
N-methyl-D-aspartate receptor subtype selective antago-
nists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-
tetrahydropyridine monkeys,” Journal of Pharmacology and
Experimental Therapeutics, vol. 290, no. 3, pp. 1034–1040,
1999.
[44] G. Linazasoro, “New ideas on the origin of L-dopa-induced
dyskinesias: age, genes and neural plasticity,” Trends in Phar-
macological Sciences, vol. 26, no. 8, pp. 391–397, 2005.
[45] P. Samadi, P. J. B ´ edard, and C. Rouillard, “Opioids and
motor complications in Parkinson’s disease,” Trends in Phar-
macological Sciences, vol. 27, no. 10, pp. 512–517, 2006.
[46] M. Jaber, B. Dumartin, C. Saund et al., “Diferential regu-
lation of tyrosine hydroxilase in the ganglia basal of mice
lacking the dopamine transporter,” European Journal of Neu-
roscience, vol. 11, no. 10, pp. 3488–3511, 1999.
[47] S. Fahn, D. Oakes, I. Shoulson et al., “Levodopa and the
progression of Parkinson’s disease,” The New England Journal
of Medicine, vol. 351, no. 24, pp. 2498–2508, 2004.
[48] C. M. Kearns and D. M. Gash, “GDNF protects nigral
dopamine neurons against 6-hydroxydopamine in vivo,”
Brain Research, vol. 672, no. 1-2, pp. 104–111, 1995.
[49] R. Kumar, A. K. Agarwal, and P. K. Seth, “Free radical-
generated neurotoxicity of 6-hydroxydopamine,” Journal of
Neurochemistry, vol. 64, no. 4, pp. 1703–1707, 1995.
[50] C. Tom´ as-Zapico and A. Coto-Montes, “A proposed mech-
anism to explain the stimulatory eﬀect of melatonin on
antioxidativeenzymes,”JournalofPinealResearch,vol.39,no.
2, pp. 99–104, 2005.
[51] S. Singh, R. Ahmed, R. K. Sagar, and B. Krishana, “Neu-
roprotection of the nigrostriatal dopaminergic neurons by
melatonin in hemiparkinsonium rat,” Indian Journal of Med-
ical Research, vol. 124, pp. 419–426, 2006.
[52] A. Hamdi, “Melatonin administration increases the aﬃnity
of D2 dopamine receptors in the rat striatum,” Life Sciences,
vol. 63, no. 23, pp. 2115–2120, 1998.
[53] L. M. V. Aguiar, S. M. M. Vasconcelos, F. C. F. Sousa, and
G.S.B.Viana,“Melatoninreversesneurochemicalalterations
induced by 6-OHDA in rat striatum,” Life Sciences, vol. 70,
no. 9, pp. 1041–1051, 2002.
[54] P. Damier, E. C. Hirsch, Y. Agid, and A. M. Graybiel, “The
substantia nigra of the human brain: II. Patterns of loss of
dopamine-containing neurons in Parkinson’s disease,” Brain,
vol. 122, no. 8, pp. 1437–1448, 1999.
[55] E. Dowd and S. B. Dunnett, “Comparison of 6-hydroxy-
dopamine-induced medial forebrain bundle and nigrostri-
atal terminal lesions in a lateralised nose-poking task in rats,”
Behavioural Brain Research, vol. 159, no. 1, pp. 153–161,
2005.
[56] B. Picconi, D. Centonze, S. Rossi, G. Bernardi, and P. Cal-
abresi, “Therapeutic doses of L-dopa reverse hypersensitivity
of corticostriatal D2-dopamine receptors and glutamatergic
overactivity in experimental parkinsonism,” Brain, vol. 127,
no. 7, pp. 1661–1669, 2004.
[57] Y.LuoandG.S.Roth,“Therolesofdopamineoxidativestress
and dopamine receptor signaling in aging and age-related
neurodegeneration,”AntioxidantsandRedoxSignaling,vol.2,
no. 3, pp. 449–460, 2000.
[58] J. T. Greenamyre and T. G. Hastings, “Parkinsons-divergent
causes convergent mechanisms,” Science, vol. 304, no. 5674,
pp. 1120–1122, 2004.
[59] Y. Glinka, M. Gassen, and M. B. H. Youdim, “Mechanism of
6-hydroxydopamine neurotoxicity,” J o u r n a lo fN e u r a lT r a n s -
mission, Supplement, no. 50, pp. 55–66, 1997.
[60] I. Antol´ ın, J. C. Mayo, R. M. Sainz et al., “Protective eﬀect
of melatonin in a chronic experimental model of Parkinson’s
disease,” Brain Research, vol. 943, no. 2, pp. 163–173, 2002.
[61] D. Acu˜ na-Castroviejo, M. Mart´ ın, M. Mac´ ıas et al., “Mela-
tonin, mitochondria, and cellular bioenergetics,” Journal of
Pineal Research, vol. 30, no. 2, pp. 65–74, 2001.
[62] F. S. D. S. Dabbeni-Sala, D. Franceschini, S. D. Skaper, and
P.Giusti,“Melatoninprotectsagainst6-OHDA-inducedneu-
rotoxicityinrats:aroleformitochondrialcomplexIactivity,”
The FASEB Journal, vol. 15, no. 1, pp. 164–170, 2001.
[63] W. S. Joo, B. K. Jin, C. W. Park, S. H. Maeng, and Y. S. Kim,
“Melatonin increases striatal dopaminergic function in 6-
OHDA-lesioned rats,” NeuroReport, vol. 9, no. 18, pp. 4123–
4126, 1998.
[64] Y.S.Kim,W.S.Joo,B.K.Jin,Y.H.Cho,H.H.Baik,andC.W.
Park, “Melatonin protects 6-OHDA-induced neuronal death
of nigrostriatal dopaminergic system,” NeuroReport, vol. 9,
no. 10, pp. 2387–2390, 1998.
[65] B. K. Jin, D. Y. Shin, M. Y. Jeong et al., “Melatonin protects
nigral dopaminergic neurons from 1-methyl-4- phenylpyri-
dinium (MPP+) neurotoxicity in rats,” Neuroscience Letters,
vol. 245, no. 2, pp. 61–64, 1998.ISRN Neurology 15
[66] G. C. Cotzias, L. C. Tang, S. T. Miller, and J. Z. Ginos,
“Melatonin and abnormal movements induced by L-dopa in
mice,” Science, vol. 173, no. 995, pp. 450–452, 1971.
[67] J.L. Venero,E. H.Absi,J.Cano,andA.Machado, “Melatonin
inducestyrosinehydroxylasemRNAexpressionintheventral
mesencephalon but not in the hypothalamus,” Journal of
Pineal Research, vol. 32, no. 1, pp. 6–14, 2002.
[ 6 8 ]C .A .I n g h a m ,S .H .H o o d ,a n dG .W .A r b u t h n o t t ,“ A
light and electron microscopical study of enkephalin-immu-
noreactive structures in the rat neostriatum after removal of
the nigrostriatal dopaminergic pathway,” Neuroscience, vol.
42, no. 3, pp. 715–730, 1991.
[69] V. M. Pickel, E. Johnson, M. Carson, and J. Chan, “Ultra-
structure of spared dopamine terminals in caudate-putamen
nuclei of adult rats neonatally treated with intranigral 6-
hydroxydopamine,” Developmental Brain Research, vol. 70,
no. 1, pp. 75–86, 1992.
[70] M. Avila-Costa, A. Gutierrez-Valdez, J. Ordo˜ nez-Librado et
al., “Time course changes of the striatum neuropil after
unilateral dopamine depletion and the usefulness of the con-
tralateral striatum as a control structure,” Neurological Re-
search, vol. 30, no. 10, pp. 1068–1074, 2008.
[71] V. Bogaerts, J. Theuns, and C. Van Broeckhoven, “Genetic
ﬁndings in Parkinson’s disease and translation into treat-
ment: a leading role for mitochondria?” Genes, Brain and
Behavior, vol. 7, no. 2, pp. 129–151, 2008.
[72] A. H. Schapira, “Mitochondria in the aetiology and patho-
genesis of Parkinson’s disease,” The Lancet Neurology, vol. 7,
no. 1, pp. 97–109, 2008.
[73] E. Crespo, M. Mac´ ıas, D. Pozo et al., “Melatonin inhibits
expression of the inducible NO synthase II in liver and lung
and prevents endotoxemia in lipopolysaccharide-induced
multiple organ dysfunction syndrome in rats,” The FASEB
Journal, vol. 13, no. 12, pp. 1537–1546, 1999.
[74] G. Escames, J. Le´ o n ,M .M a c ´ ıas, H. Khaldy, and D. Acu˜ na-
Castroviejo, “Melatonin counteracts lipopolysaccharide-in-
duced expression and activity of mitochondrial nitric oxide
synthase in rats,” The FASEB Journal, vol. 17, no. 8, pp. 932–
934, 2003.
[75] L. C. L´ opez, G. Escames, V. Tapias, P. Utrilla, J. Le´ on, and
D. Acu˜ na-Castroviejo, “Identiﬁcation of an inducible nitric
oxide synthase in diaphragm mitochondria from septic mice:
its relation with mitochondrial dysfunction and prevention
by melatonin,” International Journal of Biochemistry and Cell
Biology, vol. 38, no. 2, pp. 267–278, 2006.
[76] V. Tapias, G. Escames, L. C. L´ opez et al., “Melatonin and
its brain metabolite N1-acetyl-5-methoxykynuramine pre-
vent mitochondrial nitric oxide synthase induction in
Parkinsonian mice,” Journal of Neuroscience Research, vol. 87,
no. 13, pp. 3002–3010, 2009.
[77] M. Mart´ ın, M. Mac´ ıas, G. Escames, J. Le´ on, and D. Acu˜ na-
Castroviejo, “Melatonin but not vitamins C and E maintains
glutathione homeostasis in t-butyl hydroperoxide-induced
mitochondrial oxidative stress,” The FASEB Journal, vol. 14,
no. 13, pp. 1677–1679, 2000.
[78] R. C. Roberts and M. DiFiglia, “Evidence for synaptic pro-
liferation, reorganization, and growth in the excitotoxic le-
sioned adult rat caudate nucleus,” Experimental Neurology,
vol. 107, no. 1, pp. 1–10, 1990.
[79] B. Stephens, A. J. Mueller, A. F. Shering et al., “Evidence
of a breakdown of corticostriatal connections in Parkinson’s
disease,” Neuroscience, vol. 132, no. 3, pp. 741–754, 2005.
[80] L. S. Forno and R. L. Norville, “Ultrastructure of the neo-
striatum Huntington’s and Parkinson’s disease,” Advances in
Neurology, vol. 23, pp. 123–135, 1979.
[81] T. H. McNeill, S. A. Brown, J. A. Rafols, and I. Shoulson,
“Atrophy of medium spiny I striatal dendrites in advanced
Parkinson’s disease,” Brain Research, vol. 455, no. 1, pp. 148–
152, 1988.
[82] J. Machado-Salas, O. Ibarra, D. Martinez Fong, A. Cornejo,
J. Aceves, and J. Kuri, “Degenerative ultrastructural changes
observed in the neuropil of caudate nuclei from Parkinson’s
disease patients,” Stereotactic and Functional Neurosurgery,
vol. 54-55, pp. 297–305, 1990.
[83] S. Schuster, E. Doudnikoﬀ, D. Rylander et al., “Antago-
nizing L-type Ca2+ channel reduces development of ab-
normal involuntary movement in the rat model of L-3,4-di-
hydroxyphenylalanine-induced dyskinesia,” Biological Psy-
chiatry, vol. 65, no. 6, pp. 518–526, 2009.
[84] M. D. Neely, D. E. Schmidt, and A. Y. Deutch, “Cortical
regulation of dopamine depletion-induced dendritic spine
loss in striatal medium spiny neurons,” Neuroscience, vol.
149, no. 2, pp. 457–464, 2007.
[85] W. Shen, X. Tian, M. Day et al., “Cholinergic modulation
of Kir2 channels selectively elevates dendritic excitability in
striatopallidal neurons,” Nature Neuroscience, vol. 10, no. 11,
pp. 1458–1466, 2007.
[86] T. F. Freund, J. F. Powell, and A. D. Smith, “Tyrosine hy-
droxylase-immunoreactive boutons in synaptic contact with
identiﬁed striatonigral neurons, with particular reference to
dendritic spines,” Neuroscience, vol. 13, no. 4, pp. 1189–1215,
1984.
[87] D. S. Zahm, “An electron microscopic morphometric com-
parison of tyrosine hydroxylase immunoreactive innervation
in the neostriatum and the nucleus accumbens core and
shell,” Brain Research, vol. 575, no. 2, pp. 341–346, 1992.
[88] P. M. Groves, J. C. Linder, and S. J. Young, “5-Hydroxy-
dopamine-labeled dopaminergic axons: three-dimensional
reconstructions of axons, synapses and postsynaptic targets
in rat neostriatum,” Neuroscience, vol. 58, no. 3, pp. 593–604,
1994.
[89] P. Anglade, A. Mouatt-Prigent, Y. Agid, and E. C. Hirsch,
“Synaptic plasticity in the caudate nucleus of patients with
Parkinson’s disease,” Neurodegeneration,v o l .5 ,n o .2 ,p p .
121–128, 1996.
[90] J. J. Hanley and J. P. Bolam, “Synaptology of the nigrostriatal
projection in relation to the compartmental organization of
the neostriatum in the rat,” Neuroscience,v o l .8 1 ,n o .2 ,p p .
353–370, 1997.
[ 9 1 ] C .A .I n g h a m ,S .H .H o o d ,P .T a g g a r t ,a n dG .W .A r b u t h n o t t ,
“Plasticity of synapses in the rat neostriatum after unilateral
lesion of the nigrostriatal dopaminergic pathway,” Journal of
Neuroscience, vol. 18, no. 12, pp. 4732–4743, 1998.
[ 9 2 ] C .A .I n g h a m ,S .H .H o o d ,P .T a g g a r t ,a n dG .W .A r b u t h n o t t ,
“Synaptic plasticity in the rat neostriatum after unilateral
6-hydroxydopaminelesion of the nigrostriatal dopaminergic
pathway,”inTheBasalGanglia,C.Oh y e,M.K im ura,andJ .S.
McKenzie, Eds., pp. 157–164, Plenum Press, New York, NY,
USA, 1996.
[93] J. N. J. Reynolds, B. I. Hyland, and J. R. Wickens, “A cellular
mechanism of reward-related learning,” Nature, vol. 413, no.
6851, pp. 67–70, 2001.
[94] B. Picconi, “Eﬀects of dopamine denervation and chronic
levodopa treatment of synaptic plasticity and spontaneous
synaptic activity of stratal spiny neurones,” Society for
Neuroscience Abstract, vol. 27, pp. 292–218, 2001.
[95] P. Calabresi, P. Giacomini, D. Centonze, and G. Bernardi,
“Levodopa-induced dyskinesia: a pathological form of stri-
atal synaptic plasticity?” Annals of Neurology, vol. 47, no. 4,
pp. S60–S69, 2000.16 ISRN Neurology
[96] D. Centonze, B. Picconi, P. Gubellini, G. Bernardi, and P.
Calabresi,“Dopaminergiccontrolofsynapticplasticityinthe
dorsal striatum,” European Journal of Neuroscience, vol. 13,
no. 6, pp. 1071–1077, 2001.
[97] C. L. Parish, D. I. Finkelstein, J. Drago, E. Borrelli, and M.
K. Horne, “The role of dopamine receptors in regulating the
size of axonal arbors,” Journal of Neuroscience, vol. 21, no. 14,
pp. 5147–5157, 2001.
[98] C. K. Meshul and S. E. Tan, “Haloperidol-induced morpho-
logical alterations are associated with changes in calcium/
calmodulin kinase II activity and glutamate immunoreactiv-
ity,” Synapse, vol. 18, no. 3, pp. 205–217, 1994.
[99] G. E. Meredith, I. E. J. De Souza, T. M. Hyde, G. Tipper,
Mai Luen Wong, and M. F. Egan, “Persistent alterations
in dendrites, spines, and dynorphinergic synapses in the
nucleus accumbens shell of rats with neuroleptic-induced
dyskinesias,” Journal of Neuroscience, vol. 20, no. 20, pp.
7798–7806, 2000.
[100] C. K. Meshul and C. Allen, “Haloperidol reverses the changes
striatal glutamatergic immunolabeling following a 6-OHDA
lesion,” Synapse, vol. 36, no. 2, pp. 129–142, 2000.
[101] Y.Geinisman,F.Morrell,andL.DeToledo-Morrell,“Increase
in the number of axospinous synapses with segmented post-
synaptic densities following hippocampal kindling,” Brain
Research, vol. 569, no. 2, pp. 341–347, 1992.
[102] M. Nieto-Sampedro, S. F. Hoﬀ,a n dC .W .C o t m a n ,“ P e r -
forated postsynaptic densities: probable intermediates in
synapse turnover,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 79, no. 18, pp.
5718–5722, 1982.
[103] R.K.CarlinandP.Siekevitz,“Plasticityinthecentralnervous
system: do synapses divide?” Proceedings of the National
Academy of Sciences of the United States of America, vol. 80,
no. 11, pp. 3517–3521, 1983.
[104] Y. Geinisman, L. De Toledo-Morrell, and F. Morrell, “Aged
rats need a preserved complement of perforated axospinous
synapses per hippocampal neuron to maintain good spatial
memory,” Brain Research, vol. 398, no. 2, pp. 266–275, 1986.
[105] R. E. See, M. A. Chapman, and C. K. Menshul, “Comparison
of chronic intermit- tent haloperidol and raclopride eﬀects
on striatal dopamine release and synaptic ultra- structure in
rats,” Synapse, vol. 12, no. 2, pp. 147–154, 1992.
[106] U. Ungerstedt, “Postsynaptic supersensitivity after 6-
hydroxy-dopamine induced degeneration of the nigro-
striatal dopamine system,” Acta Physiologica Scandinavica,
Supplement, vol. 367, pp. 69–93, 1971.
[107] M. R. Avila-Costa, A. L. Gutierrez-Valdez, J. L. Ordo˜ nez-
Librado et al., “The presence of perforated synapses in the
striatum after dopamine depletion. Is this a sign of Negative
Brain Plasticity?,” in Synaptic Plasticity: New Research,T .F .
Kaiser and F. J. Peters, Eds., pp. 113–142, Nova Publishers,
New York, NY, USA, 2008.